Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Final Report on MID-NET’s Full Operations Published
August 22, 2017
- MHLW Study Group to Expand Investigation to Clinics to Determine Causes of Improper Promotional Activities
August 22, 2017
- Clinical Research Law to Apply to Indirectly Funded Programs Too, MHLW to Clarify Procedures: Official
August 21, 2017
- MHLW Advisory Panel to Review Budesonide Rectal Foam on Sept. 1
August 21, 2017
- 11 Firms Get Approval for Irbesartan Generics towards December Listing, including AG; 26 Flock to Crestor
August 16, 2017
- NIBIOHN to Promote Drug Discovery in Fields with Unmet Needs by Automating Target Discovery Using AI
August 15, 2017
- “Pediatric Treatment” Excluded from Appraisal Adjustment Factors in Pilot Program: Chuikyo
August 10, 2017
- MHLW Wants to Use Past Surveys, Overseas Examples for ICER Yardstick in CEA Pilot Program, Plan Draws Fire from Payers Reps: Chuikyo
August 10, 2017
- Calls Growing for Tougher Requirements to Receive Price Maintenance Premium: Chuikyo
August 10, 2017
- New Measures Needed to Ramp Up Generic Use: Chuikyo
August 10, 2017
- MHLW Orders Label Revisions for Warfarin, 3 Other APIs
August 7, 2017
- (Update) Katsunobu Kato Tapped as New Health Minister
August 4, 2017
- Clinical Research Law to Apply to “Nearly All Drug-Related Clinical Research” Funded by Drug Makers: MHLW
August 4, 2017
- Katsunobu Kato Tapped as New Health Minister
August 3, 2017
- “We Should Increase Our Efforts” to Promote Pharmaceutical Industry: New Health Policy Bureau Chief Takeda
August 3, 2017
- MHLW Advisory Panel Recommends Approval for Zetia/Lipitor Combo
August 3, 2017
- Bayer’s ADR Reporting Delay “Very Regrettable”: Shiozaki
August 2, 2017
- Will “Emphasize Exchange of Views” to Tackle Challenges: Pharma Bureau Chief Miyamoto
August 1, 2017
- MHLW to Support Healthcare-Related Startups from “Long-Term Perspective”: Health Minister Shiozaki
August 1, 2017
- Drug Pricing Overhaul Must Strike Balance between Benefits and Costs: Health Insurance Bureau Chief
July 31, 2017
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…